8-K: Instil Bio Highlights AXN-2510 Clinical Development and Market Opportunity in Corporate Presentation

Instil Bio's corporate presentation highlights the potential of AXN-2510, a PD-L1xVEGF bispecific antibody, particularly in NSCLC, and its ongoing clinical trials in collaboration with ImmuneOnco.

Summary

• Instil Bio's corporate presentation focuses on AXN-2510, a PD-L1xVEGF bispecific antibody targeting NSCLC.
• AXN-2510 leverages validated oncology mechanisms, addressing a significant market with PD-(L)1 inhibitors reaching ~$50B in total 2024 sales.
• The company collaborates with ImmuneOnco Biopharmaceuticals, potentially accelerating clinical development.
• Over 130 patients have been dosed with AXN-2510 to date.
• US composition of matter IP coverage extends into 2040.
• Data from a Phase 2 clinical trial of AXN-2510 in combination with chemotherapy in patients with advanced front-line NSCLC in China is anticipated in the second half of 2025.
• The presentation compares AXN-2510 favorably to competitor monotherapy Phase 1 datasets in NSCLC.
• A US-based Phase 1b/2 bridging trial initiation is anticipated before year-end 2025, assuming necessary regulatory approvals.
• Initial safety and efficacy results from approximately 60 1L patients are expected in 2H 2025.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on AXN-2510's potential, highlighting its differentiated design, clinical trial progress, and market opportunity. However, it also acknowledges the inherent risks and uncertainties associated with drug development, resulting in a moderately positive sentiment score.

Positives

• AXN-2510 targets a large market in oncology, specifically NSCLC, which is the largest market opportunity for Keytruda.
• The collaboration with ImmuneOnco allows for potentially accelerated clinical development and access to data from trials in China.
• AXN-2510 has a differentiated molecular structure with VEGF trap and ADCC-enhancement.
• The clinical development plan takes advantage of rapid enrollment in China.
• AXN-2510 demonstrates robust blockade of PD-1/PD-L1 signaling, which is enhanced by the presence of VEGF.
• The company has US composition of matter IP coverage into 2040.
• The safety profile of AXN-2510 appears manageable, with IRRs decreasing after the first infusion.

Negatives

• The development of AXN-2510 is subject to the costly and time-consuming drug product development process and the uncertainty of clinical success.
• The company relies on collaborators and other third parties, including for manufacturing and generating clinical data.
• The company is subject to the risks and uncertainties related to successfully initiating, enrolling, completing and reporting data from clinical trials.
• The company is subject to the time-consuming and uncertain regulatory approval process for product candidates across multiple indications and multiple regulatory authorities.
• The company is subject to the impact of product candidates that may compete with those that they develop.

Risks

• The company faces risks associated with macroeconomic conditions, including international conflicts and U.S.-China trade and political tensions.
• Clinical trial results obtained to date may not be indicative of results obtained in ongoing or future trials.
• The company's product candidates may not be effective treatments in their planned indications.
• The company is subject to the risk of competition from other product candidates.
• The company's cash resources may not be sufficient.

Future Outlook

The company anticipates providing updates on clinical trial progress and safety data in the coming months, with a focus on advancing AXN-2510 through clinical development and potentially achieving expedited registration strategies.

Industry Context

The presentation positions AXN-2510 within the competitive landscape of PD-(L)1 inhibitors and VEGF inhibitors, highlighting its potential to outperform existing therapies and address patient populations not currently served by these treatments. It references competitor products like Keytruda, Opdivo, Imfinzi, Tecentriq, Libtayo, Bavencio, Jemperli, ivonescimab, and BNT327.

Comparison to Industry Standards

• The document compares AXN-2510 to other PD-(L)1xVEGF bispecific antibodies such as ivonescimab (Akeso/Summit) and BNT327 (BioNTech).
• Ivonescimab showed clinically meaningful improvement over pembrolizumab in patients with PD-L1-positive NSCLC on PFS (HR:0.51, p<0.0001) and OS (HR:0.777, p=NS) in the Phase 3 HARMONi-2 trial.
• BNT327 drove clinical benefit irrespective of PD-L1 status in combination with chemotherapy in patients with TNBC.
• AXN-2510's monotherapy activity in NSCLC shows similar ORR compared to ivonescimab and BNT327 in similar patient populations.
• The safety profile of AXN-2510 is compared to ivonescimab and BNT327, showing comparable rates of TRAEs and serious TRAEs.

Stakeholder Impact

• Positive clinical trial results could benefit shareholders through increased stock value.
• Successful development and commercialization of AXN-2510 could improve treatment options for patients with NSCLC and other cancers.
• Collaboration with ImmuneOnco impacts both companies and their respective stakeholders.

Next Steps

• Initiation of a US-based Phase 1b/2 bridging trial anticipated before year-end 2025, assuming necessary regulatory approvals.
• ImmuneOnco anticipates providing an update on initial safety and efficacy results in approximately 60 1L patients in 2H 2025.
• Continued clinical development of AXN-2510 in 1L NSCLC and other solid tumors.

Key Dates

Keywords

AXN-2510, NSCLC, PD-L1xVEGF bispecific antibody, ImmuneOnco, Clinical trials, Oncology, PD-L1 inhibitors, VEGF, Bispecific antibody, Instil Bio